Xilio Therapeutics (XLO) to Release Quarterly Earnings on Monday

Xilio Therapeutics (NASDAQ:XLO) is projected to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Xilio Therapeutics (NASDAQ:XLO) last issued its earnings results on Tuesday, March 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. The company had revenue of $1.72 million during the quarter, compared to analyst estimates of $2.26 million. On average, analysts expect Xilio Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xilio Therapeutics Stock Up 2.2 %

NASDAQ:XLO opened at $0.75 on Monday. The stock has a fifty day simple moving average of $0.87 and a 200 day simple moving average of $0.93. The firm has a market capitalization of $38.62 million, a price-to-earnings ratio of -0.43 and a beta of -0.38. Xilio Therapeutics has a 1-year low of $0.63 and a 1-year high of $1.70.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.